Anonymous. Respiratory Syncytial Virus-Associated Mortality (RSV-Associated Mortality) 2019 Case Definition. 2021. Available from: https://ndc.services.cdc.gov/case-definitions/respiratory-syncytial-virus-associated-mortality-2019 [Last accessed: May 31, 2023].
2.
Anonymous. Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults. 2023. Available from: https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults/default.aspx [Last accessed: May 31, 2023].
3.
GrahamBS. The journey to RSV vaccines—Heralding an era of structure-based design. New Engl J Med, 2023; 388(7):579–581; doi: 10.1056/nejmp2216358
4.
KapikianAZ, MitchellRH, ChanockRM, et al.An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol, 1969; 89(4):405–421; doi: 10.1093/oxfordjournals.aje.a120954
5.
MazurNI, HigginsD, NunesMC, et al.The respiratory syncytial virus vaccine landscape: Lessons from the graveyard and promising candidates. Lancet Infect Dis, 2018; 18(10):e295–e311; doi: 10.1016/s1473-3099(18)30292-5
6.
McLellanJS, ChenM, JoyceMG, et al.Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science, 2013; 342(6158):592–598; doi: 10.1126/science.1243283
7.
PapiA, IsonMG, LangleyJM, et al.Respiratory syncytial virus prefusion f protein vaccine in older adults. New Engl J Med, 2023; 388(7):595–608; doi: 10.1056/nejmoa2209604
8.
Wadman. FDA Advisers Agree Maternal RSV Vaccine Protects Infants, but Are Divided on Its Safety. 2023. Available from: https://www.science.org/content/article/fda-advisers-agree-maternal-rsv-vaccine-protects-infants-divided-safety [Last accessed: May 31, 2023].
9.
WalshEE, MarcGP, ZarebaAM, et al.Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. New Engl J Med, 2023; 388(16):1465–1477; doi: 10.1056/nejmoa2213836
